Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial.

Jun Ma,Yuan Zhang,Ying Sun,Fangyun Xie,Wei-Han Hu,Guo Qing Hu,Ning Zhang,Kun Yu Yang,Xiao-Dong Zhu,Feng Jin,Zhi-Bin Cheng,Mei-Shi,Fei Han,Y. Tian,Yan Sun,Hao Yuan Mo,Jingao Li

Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial.

2019

Jun Ma
Yuan Zhang
Ying Sun
Fangyun Xie
Wei-Han Hu
Guo Qing Hu
Ning Zhang
Kun Yu Yang
Xiao-Dong Zhu
Feng Jin
Zhi-Bin Cheng
Mei-Shi
Fei Han
Y. Tian
Yan Sun
Hao Yuan Mo
Jingao Li

6003Background: GP regimen has been established as the standard first-line treatment option for patients with recurrent/metastatic NPC. However, its efficacy in locoregionally advanced disease rema...

Keywords:

Chemoradiotherapy
Randomized controlled trial
Nasopharyngeal carcinoma
Pathology
Gemcitabine
Oncology
Cisplatin
Induction chemotherapy
Medicine
Internal medicine
treatment options
Regimen
concurrent chemoradiotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations